Merit Medical Q2 adjusted EPS beats estimates, raises 2026 outlook

Merit said revenue growth was driven by notable strength in U.S. sales, which increased 10% year over year and exceeded expectations. The company also reported higher non-GAAP operating margin and non-GAAP EPS, citing improved profitability.

Therapeutic Cardiac Therapies, Endoscopy, and OEM segments all saw double-digit revenue growth year over year.

Merit raised its 2026 revenue guidance to $1.631 billion-$1.643 billion from $1.612 billion-$1.634 billion.

The company also lifted its 2026 non-GAAP EPS forecast to $4.25-$4.35 from $4.01-$4.15.

Merit said the 2026 guidance excludes potential impacts from trade policies and material acquisitions.

The current average analyst rating on the shares is "buy," with 9 "strong buy" or "buy" ratings, 2 "hold" ratings and no "sell" or "strong sell" ratings.

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."

Wall Street's median 12-month price target for Merit Medical Systems Inc is $90.00, about 11.3% above its July 29 closing price of $80.84. The stock recently traded at 19 times the next 12-month earnings, versus a P/E of 17 three months ago.

Merit Medical said U.S. revenue rose 10% year over year in the second quarter, with organic constant-currency revenue up 9%. Adjusted EPS for the quarter beat analyst expectations.